A Phase 2 interventional study of AVP-786 and Placebo in Intermittent Explosive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States — 8 open to participants now, 8 under way, none of them phase 3. Disruptive, Impulse Control, and Conduct Disorders · United States.
Among the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, this one is the 27th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 21st registered.
56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.
Browse Disruptive, Impulse Control, and Conduct Disorders studies →8 of the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 21–55 · Healthy volunteers
M.D. Anderson Cancer Center · Sites in United States
Ages 21–60
Ohio State University · Sites in United States
Ages 21–55 · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
The University of Texas at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Disruptive, Impulse Control, and Conduct Disorders studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 2 · Phase 4 4
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 48 across 46 interventional studies indexed under Disruptive, Impulse Control, and Conduct Disorders.
Median enrollment 48 across the 28 interventional studies, 48 across the 3 observational. Of the 22 that completed or were terminated, 12 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 1 study filed under Disruptive, Impulse Control, and Conduct Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05895513Ohio State UniversityPimavanserin and Aggression and Social Cognition. | 2027-01 |
| NCT06237868West Virginia UniversityrTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease | 2027-05 |
| NCT06118567Ohio State UniversityEffect of Nitrous Oxide on Aggression. | 2027-08-31 |
| NCT05712057Duke UniversityNeurostimulation Versus Therapy for Problems With Emotions | 2027-10-31 |
| NCT06639594M.D. Anderson Cancer CenterFeasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study | 2027-11-03 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
Eligible participants for this study must have a diagnosis of current IED.
This is a multicenter, randomized, double-blind, placebo-controlled study, consisting of up to 12 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were to receive AVP-786-28 (deudextromethorphan hydrobromide \[d6-DM\] 28 milligrams \[mg\]/quinidine sulfate \[Q\] 4.9 mg) once daily (OD) for the first 7 days, followed by AVP-786-28 twice daily (BID) for the next 7 days. Beginning on Day 15, participants were to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) BID for 10 weeks.
Drug: AVP-786
Participants were to receive placebo BID for 12 weeks.
Drug: Placebo
Drug pages: Deudextromethorphan · Quinidine
oral capsules
oral capsules
Change From Baseline in the Overt Aggression Scale - Modified for Outpatient Use (OAS-M) Total Aggression Score at Week 12
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M aggression domain includes 4 items: verbal assault, assault against objects, assault against others, and assault against self. The rater determines the frequency of each response (item) during the past week, and the frequency of each item is multiplied by the severity level (0 to 5), producing a raw score. This raw score is multiplied by severity weight for that item (verbal assault x 1, assault against objects x 2, assault against others x 3, and assault against self x 3). Each response is scored using a 6-point scale (0 = no events to 5 = most severe form of assault within that category). The weighted individual item scores are added to obtain the OAS-M Total Aggression score. Higher scores indicate increased aggression.
Time frame: Baseline; Week 12
Change From Baseline in the OAS-M Total Irritability Score at Week 12
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression, and irritability. The OAS-M irritability domain includes 2 global assessment items: global subjective irritability and global overt irritability. Each response is scored using a 6-point scale (0 = not at all to 5 = extreme). The 2 scores are added to create the OAS-M Total Irritability score (range = 0 to 10). Higher scores indicate increased irritability.
Time frame: Baseline; Week 12
Change From Baseline in the OAS-M Individual Items for Aggression at Week 12
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M aggression domain includes 4 items: verbal assault, assault against objects, assault against others, and assault against self. The rater determines the frequency of each response (item) during the past week, and the frequency of each item is multiplied by the severity level (0 to 5), producing a raw score. This raw score is multiplied by severity weight for that item (verbal assault x 1, assault against objects x 2, assault against others x3, and assault against self x 3). Each response is scored using a 6-point scale (0 = no events to 5 = most severe form of assault). Higher scores indicate increased aggression.
Time frame: Baseline; Week 12
Change From Baseline in the OAS-M Individual Items for Irritability at Week 12
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M irritability domain includes 2 items: global subjective irritability and global overt irritability. Each response is scored using a 6-point scale (0 = not at all; 5 = extreme). Higher scores indicate increased irritability.
Time frame: Baseline; Week 12
Change From Baseline in the Number of Intermittent Explosive Disorder (IED) Days Documented by Participants at Week 12
The IED episodes were to be documented by the participants each evening before bedtime.
Time frame: Baseline; Week 12
Change From Baseline in the Number of IED Days as Assessed by the Investigator at Week 12
The IED episodes were to be documented by the participants each evening before bedtime and reviewed by the Investigator post dose.
Time frame: Baseline; Week 12
Change From Baseline in the Number of IED Episodes at Week 12
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes.
Time frame: Baseline; Week 12
Change From Baseline in the Severity of IED Episodes at Week 12
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes and to rate the severity of the worst episode (0 = not severe at all to 10 = worst severity imaginable).
Time frame: Baseline; Week 12
Change From Baseline in the Severity of Distress From Episodes at Week 12
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes and to rate the severity of distress experienced by the episode(s) (0 = no distress to 10 = worst distress imaginable).
Time frame: Baseline; Week 12
Change From Baseline in the OAS-M: Number of Discrete IED Episodes at Week 12
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression, and irritability. The OAS-M includes information regarding the number of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) A1 aggressive episodes, and the number of DSM-5 A2 aggressive episodes experienced by the participants during the past week. The number of discrete IED episodes is calculated after an interview with the participant. Episodes identified as discrete are separated by at least 30 minutes; episodes separated by less than 30 minutes are considered a single episode.
Time frame: Baseline; Week 12
Change From Baseline in the Modified Clinical Global Impression of Severity (mCGI-S) Score for IED at Week 12
The mCGI-S is a modified version of the CGI-S scale that provides a global evaluation of the participant's IED symptoms (e.g., aggression, anger, and irritability). The mCGI-S scale measures the severity of the participant's symptoms from the clinician's perspective in the context of other participants with IED. The mCGI-S responses are scored on a 7- point scale (1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants).
Time frame: Baseline; Week 12
Change From Baseline in the Modified Clinical Global Impression of Change (mCGI-C) Score for IED at Week 12
The mCGI-C is a modified version of the CGI-C scale. The clinician rates the overall global change in the participant's IED symptoms (e.g., aggression, anger, and irritability) from Baseline at the scheduled double- blind visits. The mCGI-C responses are scored using a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse).
Time frame: Baseline; Week 12
Change From Baseline in the Modified Patient Global Impression of Severity (mPGI-S) Score for IED at Week 12
The mPGI-S is a single-question scale. Participants rate the overall global severity of their IED symptoms (e.g., aggression, anger, and irritability) using a 7-point scale (1 = normal, no symptoms; 2 = borderline symptoms; 3 = mild symptoms; 4 = moderately bad symptoms; 5 = markedly bad symptoms; 6 = severely bad symptoms; 7 = extremely bad symptoms).
Time frame: Baseline; Week 12
Change From Baseline in the Modified Patient Global Impression of Change (mPGI-C) Score for IED at Week 12
The mPGI-C is a single-question scale. Participants rate the overall global change in their IED symptoms (e.g., aggression, anger, and irritability) from Baseline at the scheduled double-blind visits. The mPGI- C responses are scored using a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse).
Time frame: Baseline; Week 12
Change From Baseline in the Sheehan Disability Scale (SDS) Score at Week 12
The SDS is a 3-item, participant-rated questionnaire used to evaluate impairments in the domains of work/school, social life or leisure activities, and family life or home responsibility. Participants rate the degree of impairment in work/school, social life or leisure activities, and family life or home responsibility as a result of IED symptoms using a visual analogue scale (0 = no impairment; 1, 2, 3 = mildly; 4, 5, 6 = moderately; 7, 8, 9 = markedly; 10 = extremely). Only those score categories with at least one participant with event are reported.
Time frame: Baseline; Week 12
Change From Baseline in the Short-Form 12-Item Health Survey (SF-12) Score at Week 12
The SF-12 is a 12-item, participant self-rated questionnaire used to measure the general health status and quality of life. The SF-12 includes questions to measure the effects of health on physical functioning, role limitations due to physical health, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores range from 0 to 100. Higher scores indicate better health status.
Time frame: Baseline; Week 12
Change From Baseline in the State-Trait Anger Expression Inventory-2 (STAXI-2) Score at Week 12
The STAXI-2 is a 57-item, participant self-rated scale used to measure the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). The STAXI-2 includes a measure of state anger, trait anger, anger expression-out, anger expression-in, anger control-out and anger control, and the anger expression index (an overall measure of the expression and control of anger). The state anger items are scored using a 4-point scale (1 = not at all to 4 = very much so) to assess the intensity of anger feelings at a particular moment. The other scales are scored using a 4- point scale to assess how frequently angry feelings are experienced, expressed, suppressed, or controlled (1 = almost never to 4 = almost always).
Time frame: Baseline; Week 12
| Milestone | AVP-786 | Placebo |
|---|---|---|
| Started | 8 | 2 |
| Completed | 3 | 1 |
| Not completed | 5 | 1 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Physician decision | 0 | 1 |
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M aggression domain includes 4 items: verbal assault, assault against objects, assault against others, and assault against self. The rater determines the frequency of each response (item) during the past week, and the frequency of each item is multiplied by the severity level (0 to 5), producing a raw score. This raw score is multiplied by severity weight for that item (verbal assault x 1, assault against objects x 2, assault against others x 3, and assault against self x 3). Each response is scored using a 6-point scale (0 = no events to 5 = most severe form of assault within that category). The weighted individual item scores are added to obtain the OAS-M Total Aggression score. Higher scores indicate increased aggression.
No measurements were reported for this outcome.
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression, and irritability. The OAS-M irritability domain includes 2 global assessment items: global subjective irritability and global overt irritability. Each response is scored using a 6-point scale (0 = not at all to 5 = extreme). The 2 scores are added to create the OAS-M Total Irritability score (range = 0 to 10). Higher scores indicate increased irritability.
No measurements were reported for this outcome.
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M aggression domain includes 4 items: verbal assault, assault against objects, assault against others, and assault against self. The rater determines the frequency of each response (item) during the past week, and the frequency of each item is multiplied by the severity level (0 to 5), producing a raw score. This raw score is multiplied by severity weight for that item (verbal assault x 1, assault against objects x 2, assault against others x3, and assault against self x 3). Each response is scored using a 6-point scale (0 = no events to 5 = most severe form of assault). Higher scores indicate increased aggression.
No measurements were reported for this outcome.
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression and irritability. The OAS-M irritability domain includes 2 items: global subjective irritability and global overt irritability. Each response is scored using a 6-point scale (0 = not at all; 5 = extreme). Higher scores indicate increased irritability.
No measurements were reported for this outcome.
The IED episodes were to be documented by the participants each evening before bedtime.
No measurements were reported for this outcome.
The IED episodes were to be documented by the participants each evening before bedtime and reviewed by the Investigator post dose.
No measurements were reported for this outcome.
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes.
No measurements were reported for this outcome.
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes and to rate the severity of the worst episode (0 = not severe at all to 10 = worst severity imaginable).
No measurements were reported for this outcome.
The IED episodes were to be documented by the participants each evening before bedtime. If the participant indicated that he/she experienced an IED episode, he/she was to document the number of episodes and to rate the severity of distress experienced by the episode(s) (0 = no distress to 10 = worst distress imaginable).
No measurements were reported for this outcome.
The OAS-M is a clinical-administered instrument designed to assess various manifestations of aggressive behavior through 2 domains: aggression, and irritability. The OAS-M includes information regarding the number of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) A1 aggressive episodes, and the number of DSM-5 A2 aggressive episodes experienced by the participants during the past week. The number of discrete IED episodes is calculated after an interview with the participant. Episodes identified as discrete are separated by at least 30 minutes; episodes separated by less than 30 minutes are considered a single episode.
No measurements were reported for this outcome.
The mCGI-S is a modified version of the CGI-S scale that provides a global evaluation of the participant's IED symptoms (e.g., aggression, anger, and irritability). The mCGI-S scale measures the severity of the participant's symptoms from the clinician's perspective in the context of other participants with IED. The mCGI-S responses are scored on a 7- point scale (1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants).
No measurements were reported for this outcome.
The mCGI-C is a modified version of the CGI-C scale. The clinician rates the overall global change in the participant's IED symptoms (e.g., aggression, anger, and irritability) from Baseline at the scheduled double- blind visits. The mCGI-C responses are scored using a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse).
No measurements were reported for this outcome.
The mPGI-S is a single-question scale. Participants rate the overall global severity of their IED symptoms (e.g., aggression, anger, and irritability) using a 7-point scale (1 = normal, no symptoms; 2 = borderline symptoms; 3 = mild symptoms; 4 = moderately bad symptoms; 5 = markedly bad symptoms; 6 = severely bad symptoms; 7 = extremely bad symptoms).
No measurements were reported for this outcome.
The mPGI-C is a single-question scale. Participants rate the overall global change in their IED symptoms (e.g., aggression, anger, and irritability) from Baseline at the scheduled double-blind visits. The mPGI- C responses are scored using a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse).
No measurements were reported for this outcome.
The SDS is a 3-item, participant-rated questionnaire used to evaluate impairments in the domains of work/school, social life or leisure activities, and family life or home responsibility. Participants rate the degree of impairment in work/school, social life or leisure activities, and family life or home responsibility as a result of IED symptoms using a visual analogue scale (0 = no impairment; 1, 2, 3 = mildly; 4, 5, 6 = moderately; 7, 8, 9 = markedly; 10 = extremely). Only those score categories with at least one participant with event are reported.
No measurements were reported for this outcome.
The SF-12 is a 12-item, participant self-rated questionnaire used to measure the general health status and quality of life. The SF-12 includes questions to measure the effects of health on physical functioning, role limitations due to physical health, bodily pain, general health perception, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores range from 0 to 100. Higher scores indicate better health status.
No measurements were reported for this outcome.
The STAXI-2 is a 57-item, participant self-rated scale used to measure the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). The STAXI-2 includes a measure of state anger, trait anger, anger expression-out, anger expression-in, anger control-out and anger control, and the anger expression index (an overall measure of the expression and control of anger). The state anger items are scored using a 4-point scale (1 = not at all to 4 = very much so) to assess the intensity of anger feelings at a particular moment. The other scales are scored using a 4- point scale to assess how frequently angry feelings are experienced, expressed, suppressed, or controlled (1 = almost never to 4 = almost always).
No measurements were reported for this outcome.
Collected over Up to Day 85. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AVP-786 | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | AVP-786 | Placebo |
|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 0/8 | 1/2 |
| Blood creatine phosphokinase increasedInvestigations | 0/8 | 1/2 |
| Electrocardiogram ST segment elevationInvestigations | 0/8 | 1/2 |
| Haematocrit decreasedInvestigations | 0/8 | 1/2 |
| Haemoglobin decreasedInvestigations | 0/8 | 1/2 |
| NauseaGastrointestinal disorders | 0/8 | 1/2 |
| VomitingGastrointestinal disorders | 0/8 | 1/2 |
| DizzinessNervous system disorders | 1/8 | 0/2 |
| HeadacheNervous system disorders | 1/8 | 0/2 |
| NervousnessPsychiatric disorders | 1/8 | 0/2 |
| Age, Continuous(years) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Mean | NA ± NA | NA ± NA | NA ± NA |
| Sex: Female, Male(Participants) | AVP-786 | Placebo | Total |
|---|---|---|---|
| Female | NA | NA | NA |
| Male | NA | NA | NA |
| Race (NIH/OMB)(Participants) | AVP-786 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | NA | NA | NA |
| Asian | NA | NA | NA |
| Native Hawaiian or Other Pacific Islander | NA | NA | NA |
| Black or African American | NA | NA | NA |
| White | NA | NA | NA |
| More than one race | NA | NA | NA |
| Unknown or Not Reported | NA | NA | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2018 to primary completion in Dec 2018, 11 months.
Results were first posted in May 2022, 3 years 4 months after primary completion. A results delay was requested in Dec 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Deudextromethorphan · Quinidine
Disruptive, Impulse Control, and Conduct Disorders →
Otsuka Pharmaceutical Development & Commercialization, Inc. →